PRELIMINARY SCIENTIFIC PROGRAMME

 

PLENARY LECTURES

New approaches towards kidney regeneration
Juan Carlos Izpisua Belmonte, La Jolla, CA, U.S.A.

Bioelectric medicine – how nerves modulate the
immune system

Kevin Tracey, Manhasset, NY, U.S.A.

Re-creating life
Steven Benner, Alachua, FL, U.S.A.

Adipose tissue expandibility, lipotoxicity and
metabolic syndrome

Antonio Vidal-Puig, Cambridge, United Kingdom
 
MINI LECTURES
 

Update on sodium-dependent phosphate transporters
Carsten Wagner, Zurich, Switzerland

Does kidney hypoxia precede albuminuria?
Fredrik Palm, Uppsala, Sweden

Genome-wide association studies in nephrology

Anna Koettgen, Freiburg, Germany

Claudins in renal function
Markus Bleich, Kiel, Germany

SGLT2 - from rare disorders to new treatment for diabetes

Luigi Gnudi, London, United Kingdom

Classifi cation and prognosis in IgA nephropathy
John Feehally, Leicester, United Kingdom

Rituximab versus cyclophosphamide for ANCAassociated vasculitis
Vladimir Tesar, Prague, Czech Republic

Subclinical pulmonary congestion is prevalent in nephrotic syndrome

Francesca Mallamaci, Reggio Calabria, Italy

Systems biology as a solution to better understand kidney disease?

Joost Peter Schanstra, Toulouse, France

New vision of Uraemic Toxicity: not a matter of a few compounds, we are facing a dreadful network
Alberto Ortiz, Madrid, Spain

Kidney disease in the elderly - is it only eGFR that matters?
Edwina Brown, London, United Kingdom

Heat stress nephropathy - implications in the setting of global warming and water shortage
Richard J. Johnson, Denver, U.S.A.

Uric acid in metabolic syndrome: culprit or innocent bystander?

Mehmet Kanbay, Istanbul, Turkey

Phosphate binders in chronic kidney disease: a systematic review of recent data
Jürgen Floege, Aachen, Germany

Inflammation and innate immunity in CKDassociated vascular disease

Danilo Fliser, Homburg/Saar, Germany

For 30 years we have been told that haemodiafi ltration is better - why haven’t we adopted it?
Angel Argiles Ciscart, Montpellier, France

“Primun non nocere” - Should statins and protein pump inhibitors be used in CKD stage 5?
David Goldsmith, London, United Kingdom

Vitamin K deficiency - does it promote vascular calcification?
Leon Schurgers, Maastricht, The Netherlands

Altered circadian hemodynamic and renal function in liver cirrhosis
Rajiv Agarwal, Indianapolis, U.S.A.

Balancing wobbles in the body sodium

Jens Titze, Nashville, U.S.A.

Navigating the critical transitional phase from CKD5 to CKD5D
Kamyar Kalantar-Zadeh, Irvine, U.S.A.

Molecular mediators of peritoneal fi brosis - role of Vitamin D Receptor Activators (VDRAs)

Rafael Selgas, Madrid, Spain

About renal and moral failure: the impact of the refugee crisis in Europe
Wim Van Biesen, Ghent, Belgium

How can we get immunized patients on our waiting list transplanted?
Torbjörn Lundgren, Stockholm, Sweden

HCV: still a problem in dialysis and kidney TP patients?

Michel Jadoul, Brussels, Belgium

Organ donation in the world - keys to success
Beatriz Dominguez-Gil, Madrid, Spain

Update on the role of mTOR inhibitors
Hallvard Holdaas, Oslo, Norway

Clinical imaging of vascular disease in chronic kidney disease

Marc Vervloet, Amsterdam, The Netherlands

What should nephrologists know about microRNAs in chronic kidney disease?

Amaryllis Van Craenenbroeck, Antwerp, Belgium

Oral or intravenous iron? - that is the question

Iain C. Macdougall, London, United Kingdom

Serum sodium: association to all-cause and cardiovascular mortality in chronic kidney disease

Philip A. Kalra, Salford, United Kingdom

Points of concern in post-AKI follow up

Norbert H. Lameire, Ghent, Belgium

Does early-start renal replacement therapy improve outcomes for patients with acute kidney injury?
John Prowle, London, United Kingdom

 

Emergence of the concept of Acute Kidney Injury                           
Garabed Eknoyan, Houston, USA
In collaboration with the
International Association for the History of Nephrology (IAHN)

 
 
SYMPOSIA
 
Track 1
Fluid and electrolytes, tubular transport, physiology
 
Kinases in control of tubular transport
The WNK-SPAK pathway in general
Dario Alessi, Dundee, United Kingdom
WNK and the regulation of blood pressure
Juliette Hadchouel, Paris, France
Kinases and potassium homeostasis
Johannes Loffing, Zurich, Switzerland
Kinases and AQP2 traffi cking
Giovanna Valenti, Bari, Italy
 
Cell biology in the renal tubule
New developments on the infl ammasome and IL-1
Hans-Joachim Anders, Munich, Germany
Lipocalin 2 / NGAL: a player at the crossroad of different signalling pathways leading to CKD progression
Fabiola Terzi, Paris, France
Endolysosomal disorders
Olivier Devuyst, Zurich, Switzerland
Autophagy and senescence in proximal tubule
Roland Schmitt, Hannover, Germany
 
Renal mineral handling - what’s new?
Renal phosphate handling
Carsten Wagner, Zurich, Switzerland
Magnesium
Markus Ketteler, Coburg, Germany
FGF23-Klotho signalling in the kidney
Hannes Olauson, Stockholm, Sweden
Modeling calcium transport
Aurélie Edwards, Paris, France
 
Track 2
Hereditary disorders, development, pregnancy, paediatric nephrology
 
Actualities and new questions in adult polycystic kidney disease

Clinical scores in ADPKD: advantages and limitations
Ron T. Gansevoort, Groningen, The Netherlands
Signaling pathways in ADPKD: Novel targets for treatment?
Speaker to be confirmed
ADPKD - novel aspects on the role of vasopressin
Olivier Devuyst, Zurich, Switzerland
ADPKD and mineral and bone disease - what are the links?
Pieter Evenepoel, Leuven, Belgium

 
Genetics of blood pressure regulation
Population studies
Speaker to be confirmed
Salt sensitivity: Insights from evolution
Matthew Bailey, Edinburgh, United Kingdom
Resistant hypertension and pharmacogenomics
Speaker to be confirmed
The WNK-SPAK pathway: Relevance for clinicians
Johannes Loffing, Zurich, Switzerland
 
Developmental origin of health and disease
Birth weight and risk of CKD
Bjørn Egil Vikse, Haugesund, Norway
Fetal programming of renal aging
Uyen Huynh-Do, Bern, Switzerland
Targeting epigenetics of chronic kidney disease
Michael Zeisberg, Göttingen, Germany
An update on inducible pluripotent stem cells
Joseph Bonventre, Boston, USA
 
Immunology and hypertension during pregnancy
Pregnancy in kidney transplanted women, immunology and outcomes
Anna Varberg Reisaeter, Oslo, Norway
Lupus and pregnancy
Uyen Huynh-Do, Bern, Switzerland
Renal hemodynamic changes in health and disease
Speaker to be confirmed
Preeclampsia - novel approaches for treatment
Speaker to be confirmed
 
Track 3
Glomerular diseases, general clinical nephrology
 
Non-invasive biomarkers of renal fi brosis or progressive kidney diseases
Humoral factors
Christos Chatziantoniou, Paris, France
Non-invasive diagnostic of renal fibrosis
Peter Boor, Aachen, Germany
Proteomics for chronic renal diseases
Gian Marco Ghiggeri, Genoa, Italy
Metabolomics and-or Uremic Toxins
Raymond Vanholder, Ghent, Belgium
 
Focal segment glomerulosclerosis - new insights into pathomechanisms
Lessons from the zebrafish
Jaakko Patrakka, Stockholm, Sweden
Glomerular disease signalling in FSGS
Tobias Huber, Freiburg, Germany
How does glomerular hypertrophy occur?
Marcus J. Moeller, Aachen, Germany
Novel pathways in FSGS: Identification of a driver for the pathogenic Parietal Epithelial Cells
Pierre-Louis Tharaux, Paris, France
 
Glomerulonephritis: What is new in 2017?
Membranous GN
Pierre Ronco, Paris, France
IgAN
Jürgen Floege, Aachen, Germany
Treatment of minimal change GN and FSGS
Piero Ruggenenti, Bergamo, Italy
Heparanase - is it nephroprotective in nephrotic syndrome?
Suheir Assady, Haifa, Israel
 
Hepatitis C, hepatitis B and HIV in the era of effective antivirals
Hepatitis C and direct antivirals - clinical applications and indications
Annette Bruchfeld, Stockholm, Sweden
Hepatitis C treatment: before or after renal transplantation?
Michel Jadoul, Brussels, Belgium
Hepatitis B - update on treatment and vaccination
Fabrizio Fabrizi, Milan, Italy
Chronic kidney disease in the ageing HIV-positive population
Lene Ryom, Copenhagen, Denmark
 
Complement abnormalities associated with C3 glomerulopathy
C3 glomerulopathy: lessons from animal models
Matthew Pickering, London, United Kingdom
Genetic abnormalities in C3GN
Santiago Rodriguez de Cordoba, Madrid, Spain
Acquired abnormalities in C3GN
Speaker to be confirmed
Recurrence of GC3 after renal transplantation, risk factor, treatment and prevention
Moglie Le Quintrec, Montpellier, France
 
Fibrosis complicating several scenarios in chronic kidney disease
New mechanisms of cardiac fibrosis and failure in chronic kidney disease
Javier Diez, Pamplona, Spain
Role of ALK-1 and endoglin, members of the TGF-beta receptor complex, in kidney fi brosis
José M. Lopez-Novoa, Salamanca, Spain
Renal fi brosis - should we treat it? No!
Hans-Joachim Anders, Munich, Germany
Renal fibrosis - should we treat it? Yes!
Rafael Kramann, Aachen, Germany
 
Track 4
CKD - pathophysiology, epidemiology, prevention, progression, ageing
 
Chronic kidney disease - a clinical model of premature ageing
Reasons why CKD patients undergo premature ageing
Peter Stenvinkel, Stockholm, Sweden
Ageing and chronic inflammation - lessons from non-renal chronic debilitating diseases
Jeroen Kooman, Maastricht, The Netherlands
Recovering Klotho in CKD - is this an achievable challenge?
Adriana Dusso, Oviedo, Spain
Can ageing be drugged?
Paul Shiels, Glasgow, United Kingdom
 
Kidney biomimcry - what can Nephrologists learn from the animal kingdom?
Lessons on how animals store water in relation to global warming, obesity and CKD
Richard J. Johnson, Denver, U.S.A.
Uric acid, fructose and metabolic syndrome. An evolutionary approach to today’s epidemic
Miguel Lanaspa, Denver, U.S.A.
What can we learn from the animal kingdom about renal sodium and water handling?
Nadine Bouby, Paris, France
What can hibernating bears teach us on how to prevent muscle and bone loss in CKD?
Peter Stenvinkel, Stockholm, Sweden
 
Biomarkers in chronic kidney disease

Prognostic and predictive biomarkers in CKD
Gert Mayer, Innsbruck, Austria
Uric acid and renal outcomes - do we need further evidence to lower uric acid in asymtomatic patients?
José Luño, Madrid, Spain
FGF23-Klotho axis and myocardial alterations in CKD
Danilo Fliser, Homburg/Saar, Germany
Cathepsins and endostatin in the cardiorenal continuum
Johan Ärnlöv, Uppsala, Sweden

 
Salt and the diseased kidney: an evil relationship or a too blamed one?
What are the links between sodium and the immune system?
Speaker to be confirmed
Effect of salt on the cutaneous antimicrobial barrier function
Jens Titze, Nashville, U.S.A.
Salt restriction in hemodialysis patient - just a chimera?
Gerjan Navis, Groningen, The Netherlands
How far can we go with low salt diet in elderly CKD patients?
Mustafa Arici, Ankara, Turkey
 
The uremic microbiota - Implications for the uremic phenotype and treatment
The gut microbiome and its relation to metabolic alterations in CKD
Griet Glorieux, Ghent, Belgium
The influence of renal transplantation on retained microbial-human co-metabolites
Bjorn Meijers, Leuven, Belgium
The leaky gut - relationship with the microbiota
Pieter Evenepoel, Leuven, Belgium
Should we drug the bug - how can diet and drugs influence the gut flora?
Denis Fouque, Lyon, France
 
Physical exercise and lifestyle management in chronic kidney disease

Physical exercise in CKD. Evidence from clinical trials
Carmine Zoccali, Reggio Calabria, Italy
The Excite trial: results of a home based exercise in dialysis patients
Francesca Mallamaci, Reggio Calabria, Italy
Modifiable lifestyle factors in high risk individuals with CKD
Rainer Oberbauer, Vienna, Austria
Self-management and e-health initiatives
Andrea W. Evers, Leiden, The Netherlands

 
New insigths into progressive chronic kidney disease
Progressive CKD - who is at risk?
Manuel Praga, Madrid, Spain
Effects of stress-induced dedifferentiation of renal epithelia in chronic kidney disease
Hermann-Josef Groene, Heidelberg, Germany
Clinical utility of biomarkers for CKD progression
Gunnar Heine, Homburg/Saar, Germany
Current treatment options for “fast” CKD progressors
Piero Ruggenenti, Bergamo, Italy
 
Epidemiology and CKD-MBD
Causal inference from observational data in CKD research
Miguel Hernan, Boston, U.S.A.
CKD-MBD targets: Contribution of COSMOS
Jorge B. Cannata-Andía, Oviedo, Spain
COSMOS: PTH lowering drugs andvparathyroidectomy - Impact on outcomes
Speaker to be confirmed
Clinical use of ALP and PTH in discrimination of low vs high bone turnover
Goce Spasovski, Skopje, F.Y.R. of Macedonia
 
Track 5
End Stage Renal Disease, haemodialysis
 
Are we offering good care to the elderly with kidney disease?
The characteristics of incident dialysis patients from the sixties to the present: age and co-morbidities
Kitty J. Jager, Amsterdam, The Netherlands
Elderly patients reaching end-stage renal disease: treat or not to treat?
Maurice Laville, Lyon, France
If we treat elderly patients with dialysis - is there a point to stop?
Edwina Brown, London, United Kingdom
Is advanced care planning the solution and do we apply it?
José Antonio Sanchez-Tomero, Madrid, Spain
 
Iron - the bright and the dark side
Iron in dialysis - is it a panacea or toxin?
Jolanta Malyszko, Bialystok, Poland
Iron and infections - do we put fuel on the fire?
Günter Weiss, Innsbruck, Austria
Iron overload - should Nephrologists care?
Iain C. Macdougall, London, United Kingdom
Fe-based phosphate binders - a role in iron supplementation or a dead end?
Markus Ketteler, Coburg, Germany
 
Residual renal function in HD - an opportunity for improvement
Longer or more frequent dialysis: is residual renal function best at stake?
Charles Chazot, Sainte Foy Les Lyon, France
"To pee or not to pee” - is there a place for diuretics in dialysis patients?
Angel Argiles Ciscart, Montpellier, France
Should we stop ACE/ARBs in CKD stage 5?
Muhammad Magdi Yaqoob, London, United Kingdom
Assessment of fl uid overload in dialysis patients
Adrian Covic, Iasi, Romania
 
Heart failure in chronic kidney disease
Uremic toxins and the heart
Ziad Massy, Paris, France
Treatment of hyperkalemia in dialysis patients: what is on the horizon?
Matthew R. Weir, Baltimore, U.S.A.
Rhythm disturbances - the silent killer
Christiane Drechsler, Würzburg, Germany
What is the utility of cardiovascular biomarkers?
Jesus Egido, Madrid, Spain
 
Bone loss in chronic kidney disease
Interrelations of Wnt inhibitors, vascular calcification and bone loss
Jorge B. Cannata-Andía, Oviedo, Spain
Vitamin D - a drug for all seasons?
David Goldsmith, London, United Kingdom
Sclerostin in CKD - is it a mediator of vascular and bone disease or just another biomarker?
Vincent Brandenburg, Aachen, Germany
Novel treatment of adynamic bone disease
Mario Cozzolino, Milan, Italy
 
Hemodialysis anticoagulation: present and future
Anticoagulation for extracorporeal therapies
Andrew Davenport, London, United Kingdom
Is regional citrate anticoagulation the future of hemodialysis?
Jadranka Buturovic-Ponikvar, Ljubljana, Slovenia
Citrate anticoagulation for CRRT - current status and challenges
Helena Maria Oudemans-Van Straaten, Amsterdam, The Netherlands
Citrate in dialysate: standard for the next decade hemodialysis?
Speaker to be confirmed
 
Muscle mass and fat mass in chronic kidney disease - assessment and implications
Assessment of Protein-Energy Wasting - quest for the gold standard
Pieter M. Ter Wee, Amsterdam, The Netherlands
The dual impact of under- and overweight on morbidity and mortality in chronic kidney disease
Juan Jesus Carrero, Stockholm, Sweden
Can chronic kidney disease patients improve their muscle mass by nutritional means?
Denis Fouque, Lyon, France
Physical activity intervention - is it realistic in sedentary dialysis patients?
Amaryllis Van Craenenbroeck, Antwerp, Belgium
 
The ugly new faces of old enemies - bacterial infections in nephrology
Bacteriemia and sepsis - relation to hemodialysis catheters
James Tattersall, Leeds, United Kingdom
New aspects on PD-related peritonitis
Norbert H. Lameire, Ghent, Belgium
Update on urinary tract infection and urosepsis for the Nephrologist
Jonathan G. Fox, Glasgow, United Kingdom
“What´s the cause of those so ill? - that damned elusive difficile”. The emerging treat of Clostridium difficile infections
Marcin Adamczak, Katowice, Poland
 
Track 6
Home therapies, peritoneal dialysis
 
Use of home-based therapies in Europe - a missing link?
PD use is declining in Europe - why?
Marlies Noordzij, Amsterdam, The Netherlands
Should we start PD acutely?
Speaker to be confirmed
We should enable patients to decide
Olof Heimbürger, Stockholm, Sweden
Why stimulating home based therapies is an economical imperative that has ethical consequences
Bert Bammens, Leuven, Belgium
 
Peritoneal dialysis and cardiovascular risk
Achieving euvolaemia in PD patients - lessons from a clinical case
Jeroen Kooman, Maastricht, The Netherlands
Biomarkers for vascular calcification in peritoneal dialysis
Ricardo Correa-Rotter, Mexico City, Mexico
Blood pressure targets in PD - what is the evidence?
James Heaf, Copenhagen, Denmark
Gut microbiota in PD
Griet Glorieux, Ghent, Belgium
 
Dialysis for the ageing population
Dialysis in the elderly - a different ball game?
Wim Van Biesen, Ghent, Belgium
Geriatric assessment as standard nephrological care
Edwina Brown, London, United Kingdom
What outcomes should Nephrologists measure in the ageing dialysis population?
Ingrid Os, Oslo, Norway
Dialysis withdrawal - when, how and why
Monika Lichodziejewska-Niemierko, Gdańsk, Poland
 
Track 7
Transplantation, immunology
 
Management of complications after kidney transplantation (I)
Is severe obesitys of any harm in living kidney donation?
Andrzej J. Więcek, Katowice, Poland
Pretransplant weight loss in dialysis patients - how important is it?
Mehmet Sukru Sever, Istanbul, Turkey
Evolution and management of bone disease after transplantation
Pieter Evenepoel, Leuven, Belgium
Evolution and management of arterial stiffness after renal transplantation
George Reusz, Budapest, Hungary
 
Management of complications after kidney transplantation (II)
Malignancy after kidney transplantation - what should nephrologists know?
Alicja Debska-Slizien, Gdansk, Poland
The natural history of kidney graft cortical microcirculation
Rafael Selgas, Madrid, Spain
Why should we assess the biological age of the renal transplant?
Paul Shiels, Glasgow, United Kingdom
Management of chronic graft rejection
Daniel Abramowicz, Antwerp, Belgium
 
Therapeutic use of renal progenitor and adult renal cells for kidney regeneration
Therapeutic use of renal progenitor cells for chronic kidney disease
Benedetta Bussolati, Turin, Italy
Therapeutic use of renal progenitor cells for acute kidney disease
Joseph Bonventre, Boston, USA
Organoid models and applications in biomedical research
Giuseppe Remuzzi, Bergamo, Italy
Cell therapy with adult renal-derived cells - clinical experience
Torbjörn Lundgren, Stockholm, Sweden
 
Immunosuppression after renal transplantation - less, more or appropriate?
 
Innovative monitoring tools of immunosuppression after kidney transplantation
Rainer Oberbauer, Vienna, Austria
Mesenchymal stem cell transfusion for desensitization of positive lymphocyte crossmatch before kidney transplantation
Gamal Saadi, Cairo, Egypt
Monitoring of immunosuppressive drugs metabolites in kidney transplantation - helpful or dispensable?
Leszek Paczek, Warsaw, Poland
The fine line between under- and overimmunosuppression - impact of natural products and dietary supplements
Steven Gabardi, Boston, U.S.A.
 
Advances in drug treatment after renal transplantation
 

Steroid-free or not?
Paolo Malvezzi, Grenoble, France
Update on Belatacept and IdeS in renal transplantation
Bengt Fellström, Uppsala, Sweden
Any new immunosuppressives on the horizon?
Josep M. Grinyó, Barcelona, Spain
Update on antiviral treatment in kidney transplant recipients
Fabrizio Fabrizi, Milan, Italy

 
Track 8
Hypertension, diabetes, vascular disease
 
Novel aspects of management of blood pressure in chronic kidney disease
How to obtain the target blood pressure in CKD: is it a SPRINT or a marathon?
Rajiv Agarwal, Indianapolis, U.S.A.
Renal denervation and CKD progression
Peter J. Blankestijn, Utrecht, The Netherlands
Mineralocorticoid receptor blockers in CKD patients
Matthew R. Weir, Baltimore, U.S.A.
Optimal treatment for drug-resistant hypertension
Speaker to be confirmed
 
Cardiovascular disease in patients with chronic kidney disease - double trouble

Role of Klotho and FGF23 in uremic cardiomyopathy
Marc Vervloet, Amsterdam, The Netherlands
Hormones and uremic cardiomyopathy
Andrzej J. Więcek, Katowice, Poland
Heart failure in kidney patients - a diffi cult diagnosis with poor prognosis
Speaker to be confirmed
What´s new in the diagnosis and treatment of coronary artery disease in CKD?
Philip A. Kalra, Salford, United Kingdom

 
SGLT-2 inhibitors in diabetic kidney disease

SGLT-2: role in physiology and pathophysiology
Dominique Prié, Paris, France
SGLT-2: renal pathophysiology
Luigi Gnudi, London, United Kingdom
SGLT-2 inhibition: clinical data
Christoph Wanner, Würzburg, Germany
SGLT-2 inhibition: effects on blood pressure
Speaker to be confirmed

 
Novel drugs in chronic kidney disease
Update on endothelin and mineralocorticoid receptor antagonists
Johannes F.E. Mann, Munich, Germany
Update on anticoagulants in CKD
Karolina Szummer, Stockholm, Sweden
CCR2 inhibition: a panacea for diabetic kidney disease
Matthew R. Weir, Baltimore, U.S.A.
HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond
Kai-Uwe Eckardt, Erlangen, Germany.
 
Diabetic nephropathy - how should it be treated?
HbA1c - is it optimal for glycemic control assessment in chronic kidney disease?
Loreto Gesualdo, Bari, Italy
Is there still a place for dual RAS blockade in nephroprotection of diabetic patients?
Giuseppe Remuzzi, Bergamo, Italy
Treatment of hyperglycemia in chronic kidney disease
Bo Feldt-Rasmussen, Copenhagen, Denmark
Haemodialysis-induced hypoglycaemia and glycaemic disarrays in the uremic milieu
Ivan Rychlik, Prague, Czech Republic
 
Diabetic nephropathy - new trends in 2017

Diabetic nephropathy in Europe: Epidemiology and choice of renal replacement therapy
Marlies Noordzij, Amsterdam, The Netherlands
New experimental evidence in pathogenesis of diabetic nephropathy
Bo Feldt-Rasmussen, Copenhagen, Denmark
Optimal treatment of diabetic patient with albuminuria
Peter Rossing, Gentofte, Denmark
Clinical care of diabetic kidney disease: advantages of the early referral
Alberto Martinez-Castelao, Barcelona, Spain

 
Track 9
Acute Kidney Injury, intensive care nephrology
 
Detection and prevention of AKI in patients at risk - state-of-the art 2017
Are new AKI biomarkers of any clinical advantage?
Raymond Vanholder, Ghent, Belgium
Tubular dysfunction as a pathway for acute kidney injury
Fredrik Palm, Uppsala, Sweden
Ischaemic preconditioning: promise unfulfilled
Muhammad Magdi Yaqoob, London, United Kingdom
Are there novel pharmacological tools for AKI prevention in 2017?
Norbert H. Lameire, Ghent, Belgium
 
Management of AKI patients in the ICU
Blood pressure management in ICU patients with AKI
Speaker to be confirmed
Diuretics in AKI - yes, no or maybe?
Fernando Liaño, Madrid, Spain
RRT in AKI: when, how and how much?
Claudio Ronco, Vicenza, Italy
Anticoagulation strategies for AKI patients requiring RRT
Achim Joerres, Cologne, Germany
 
Special condition in the ICU requiring nephrological advice

Patients with life-threatening systemic disease at the ICU
Vladimir Tesar, Prague, Czech Republic
Management of cardiorenal syndromes in the ICU
Claudio Ronco, Vicenza, Italy
How much antibiotics does your RRT consume per day? Pharmacokinetics of critically ill patients undergoing RRT
Jan T. Kielstein, Braunschweig, Germany
An overview of treatment of crush syndrome
Mehmet Sukru Sever, Istanbul, Turkey

 
 
SPECIAL & JOINT SYMPOSIA
 
NDT Polar Views. Risk prediction tools in stage 5 D CKD: precious instruments for risk stratifi cation or just gadgets of electronic wizardry?
NDT
CON. Most clinical risk scores are useless
Friedo W. Dekker, Leiden, The Netherlands
PRO. It’s time to implement risk scores in CKD care
Navdeep Tangri, Winnipeg, Canada
 
ERA-EDTA Registry
ERA-EDTA Registry
Ten year trends of renal transplantation in recipients aged 75 years and older
Maria Pippias, Amsterdam, The Netherlands
Characteristics and outcomes of patients with systemic sclerosis (scleroderma) requiring RRT
Speaker to be confirmed
Modification of the “long gap” phenomenon by hemodialysis treatment time
Speaker to be confirmed
Gender differences in advanced CKD
Kitty Jager, Amsterdam, The Netherlands
Recovery of renal function in paediatric RRT
Marjolein Bonthuis, Amsterdam, The Netherlands
 
Optimizing care in advanced CKD and the transition to dialysis: Insights from DOPPS Program
DOPPS

The DOPPS Program: invitation to collaborators
Hugh Rayner, Birmingham, United Kingdom
CKDopps: Improving outcomes in advanced CKD and the transition to dialysis
Helmut Reichel, Villingen-Schwenningen, Germany
DOPPS: Impact of clinical practices on early mortality among HD patients
Speaker to be confirmed
PDOPPS: Predictors of early successful PD use
Martin Wilkie, Sheffield, United Kingdom
EURODOPPS: Selected findings from the calls for proposals
Speaker to be confirmed

 
Ethics in scientific research
Ethics Committee
- Ethics of intervention in small or large scale disasters
- Do ethics and health economics always go hand to hand?
- The interaction between public policy/financial constraints and ethical values in treating patients with renal failure
- What is more ethical for deceased graft donation: opting in or opting out?
 
YNP – Young Nephrologists’ Platform
YNP
 
Late Breaking Clinical Trials  
 
The Lancet
The Lancet
 
ERA-EDTA &
European Society of Cardiology (ESC)
ESC
 
ERA-EDTA &
European Society of Hypertension (ESH)
ESH
 
ERA-EDTA &
European Society for
Paediatric Nephrology (ESPN)
ESPN
 
ERA-EDTA &
Japanese Society of Nephrology (JSN)
JSN
 
American Society of Nephrology
Highlights (ASN)
ASN
 
ERA-EDTA & European Association of the Study
of Diabetes (EASD)
 
 
 
CME COURSES
 
Cross-talk in Renal Epidemiology
ERA-EDTA Registry
ERA-EDTA Registry
Sample size calculations
Marlies Noordzij, Amsterdam, The Netherlands
The contribution of cross sectional studies to nephrology
Giovanni Luigi Tripepi, Reggio Calabria, Italy
A joint model to describe CKD progression and mortality in CKD patients: a practical guide
Katharina Brück, Amsterdam, The Netherlands
Restricted mean survival time: an alternative to the hazard ratio
Cecile Couchoud, Saint Denis La Plaine, France
The importance of considering competing treatment affecting prognosis in RCTs
Speaker to be confirmed
Marginal structural models in clinical research: when and how to use them
Pietro Ravani, Calgary, Canada
Can we use routine primary care data to estimate how many people with CKD there are? An example using UK primary care data
Dorothea Nitsch, London, United Kingdom
 
 
News in the pathogenesis and treatment of glomerular disease
IWG (Immunonephrology Working Group)
IWG

Part I - Complement mediated diseases: pathogenesis, new entities, upcoming treatments, how to handle expensive drugs
Complement activation in immune-mediated glomerular disease
Mohamed R. Daha, Leiden, The Netherlands
Complement staining in kidney biopsy (C3, C4, C5b-9)
Pablo Cannata-Ortiz, Madrid, Spain
Complement in ANCA-associated Vasculitis - new therapeutic target?
Annette Bruchfeld, Stockholm, Sweden
Complement activation in IgA nephropathy, membranous nephropathy and FSGS
Yasar Caliskan, Istanbul, Turkey
Targeting complement in atypical hemolytic uremic syndrome and C3 glomerulopathy
Giuseppe Remuzzi, Bergamo, Italy

Part II - Individualized (personalized) treatment of glomerular disease – is it already possible?
Personalized immunomonitoring and treatment in lupus nephritis
Hans-Joachim Anders, Munich, Germany
Personalized monitoring and treatment in membranous nephropathy
Jack F.M. Wetzels, Nijmegen, The Netherlands
Personalized approach to IgA nephropathy, is supportive care the response for most patients?
Renato Monteiro, Paris, France
Personalized treatment in ANCA-associated vasculitis
Mårten Segelmark, Linköping, Sweden
Hematuria in glomerular disease - is it important for the outcome of the patients?
Jesus Egido, Madrid, Spain

 
 
Novel therapeutic opportunuties to decrease cardiovascular risk in CKD
EURECA-m Working Group (EUropean REnal and CArdiovascular Medicine)
EURECA-m
Part I - Novel risk factors and structural cardiovascular damage
Chronic infections and cardiovascular risk: a poorly understood link
Charles Ferro, Birmingham, United Kingdom
Atrial fibrillation in CKD
Gunnar Heine, Homburg/Saar, Germany
Novel faces of FGF23; iron deficiency, inflammation, insulin resistance, proteinuria and acute kidney injury
Mehmet Kanbay, Istanbul, Turkey
Vascular calcifications in end stage kidney disease
Marianne Verhaar, Utrecht, The Netherlands

Part II - Ions and blood pressure
Cardiovascular risk in CKD: novel insights from the NEFRONA and ILERVAS studies
Jose M Valdivielso, Lérida, Spain
Early Vascular Aging (EVA syndrome) in CKD/ESRD
Gérard London, Fleury-Mérogis, France
Blood pressure variability in patients with chronic kidney disease
Pantelis Sarafidis, Thessaloniki, Greece
ABPM in renal transplant patients: for everybody and why?
Francesca Mallamaci, Reggio Calabria, Italy
 
 
Hot topics in the management of pre- and postkidney transplantation
DESCARTES Working Group (Developing Education Science and Care for Renal Transplantation in European States) -
In collaboration with EKITA, the Organ Expert Section of ESOT on kidney transplantation in Europe
Descartes
EKITA
Survival with transplantation and dialysis - implications for access to the waiting list?
Gabriel C. Oniscu, Edinburgh, United Kingdom
You and your patient decide: take an old kidney or remain on dialysis
Julio Pascual, Barcelona, Spain
Pre-Transplant cardiac work-up before waitlisting - What’s in it for the individual patient
Patrick Mark, Glasgow, United Kingdom
When and how to adjust immunosuppressive therapy in patients with post-transplant malignancy
Speaker to be confirmed
Treatment of recurrent IgA nephropathy after kidney transplantation
Giuseppe Grandaliano, Foggia, Italy
Managing drug interactions with new drugs in transplant recipients: practical recommendations for nephrologists
Umberto Maggiore, Parma, Italy
How to desensitize HLA incompatible kidney transplant recipients
Lionel Rostaing, Grenoble, France
 
 
Impoving the outcome of dialysis
(Eudial Working Group - European Dialysis Working Group)
EUDIAL

Starting haemodialysis - an incremental approach
Carlo Basile, Acquaviva delle Fonti, Italy
Dialysis adequacy does everyone need the same Kt/V
Andrew Davenport, London, United Kingdom
Assessing volume in haemodialysis patients are lung ultrasound and bioimpedance needed
Sandip Mitra, Manchester, United Kingdom
Preventing intra-dialytic hypotension or does haemdiafiltration improve growth in children with end stage kidney disease
Rukshana Shroff, London, United Kingdom
Debate:
Haemodiafiltration has no advantage over high flux haemodialysis
Steven Van Laecke, Ghent, Belgium
High volume haemodiafi ltration, the new standard of treatment
Peter J. Blankestijn, Utrecht, The Netherlands

 
 
DIABESITY: Diabetes and Obesity in Renal Disease
(DIABESITY - Working Group researching on the nephrological impact in relation to diabetes and obesity)
Diabesity
Hemodialysis or peritoneal dialysis treatment for obese diabetic patients?
Robert Ekart, Maribor, Slovenia
SGLT2 inhibitors for diabetic renal disease and obesity: a new weapon in our pharmacological armamentarium?
Christoph Wanner, Würzburg, Germany
Reducing weight to slow GFR decline in patients with obesity and diabetes: The CRESO study
Piero Ruggenenti, Bergamo, Italy
Precision medicine in diabetic nephropaty in obesity-time rethink treatment?
Peter Rossing, Gentofte, Denmark
How can obesity-related nephropathy be identified in clinical practice?
Manuel Praga, Madrid, Spain
Renal histology in patients with type 2 diabetes without proteinuria
Esteban Porrini, Tenerife, Spain
 
 
Phosphate and Nutrition in CKD
ERN Working Group (European Renal Nutrition)
ERN

Intestinal phosphate absorption from nutrients
Pablo Antonio Ureña Torres, Saint Ouen, France
Lowering phosphate intake without PEW: is it possible during CKD, dialysis and transplantation?
Pieter M. Ter Wee, Amsterdam, The Netherlands
Phosphorus additive in food: a health risk for CKD patients
Adamasco Cupisti, Pisa, Italy
How can we modify nutrient habits toward a lower phosphate intake?
a) Age and psychosocial factors
Speaker to be confirmed
b) Education and information: make a choice, nutritional education program
Stanislas Trolonge, Bordeaux, France
Mediterranean diet: an optimal diet for CKD patients?
Miguel A. Martinez-Gonzalez, Pamplona, Spain

 
 
Diagnosis and management of inherited kidney diseases: What’s New?
WGIKD (Working Group on Inherited Kidney Disorders)
WGIKD
Part I
Collagen IV glomerulopathies: An underdiagnosed phenotypic chameleon?
Constantinos Deltas, Nicosia, Cyprus
Alport Syndrome: A treatable hereditary kidney disease
Oliver Gross, Göttingen, Germany
NGS podocytopathy panel screening in adults with CKD of unknown origin: Findings from the GCKD Study
Anna Koettgen, Freiburg, Germany

Part II
C3 glomerulopathy: Role of complement for pathogenesis and treatment
Marina Vivarelli, Rome, Italy
Advances in molecular understanding of cystinosis: Implications for therapy
Speaker to be confirmed
Preimplantation genetic diagnosis for inherited renal diseases
Nine Knoers, Utrecht, Netherlands
The European Reference Network for Rare Kidney Diseases
Franz Schaefer, Hidelberg, Germany
 
 
Implementation of the KDIGO update on CKD-MBD
CKD-MBD (Working Group on Chronic Kidney Disease - Mineral and Bone Disorders)
CKD-MBD

Part I
Should the presence of vascular calcification influence choice of phosphate binder?
Speaker to be confirmed
Phosphate binder therapy in predialysis? When and how?
Adrian Covic, Iasi, Romania
Current insights into dietary intervention to modulate phosphate concentration and balance
Vincent Brandenburg, Aachen, Germany

Part II
Screening for fracture risk in CKD
Pablo Antonio Ureña Torres, Saint-Ouen, France
Position in CKD of novel compounds to treat bone disease
Sandro Mazzaferro, Rome, Italy
Any position left for active vitamin D?
Mario Cozzolino, Milan, Italy
Invited lecture:
Update on CKD-MBD in Pediatrics
Rukshana Shroff, London, United Kingdom

 
 
The new uraemic toxins and innovative endeavors to treat uraemic toxicity
EUTox Working Group (European Uremic Toxin)
EUTOX
An update on uremic toxins: concepts and novelties
Flore Duranton, Montpellier, France
Lanthionine, a prospective novel uremic toxin, in the context of sulfur metabolism derangement in uremia
Alessandra Perna, Naples, Italy
Aryl hydrocarbon receptor (AHR) and the uremic toxins
Stéphane Burtey, Marseille, France
Can we dominate and master renal cells to remove uraemic toxins on request?
Rosalinde Masereeuw, Utrecht, Netherlands
Using convection at its best to increase uraemic toxin removal
Angel Argiles Ciscart, Montpellier, France
Dissociating protein bound toxins to remove them
Joachim Jankowski, Aachen, Germany
Adsorptive strategies to remove uraemic toxins
Tobias Beck, Aachen, Germany
 
Good guidance can save your patient
European Renal Best Practice
ERBP
Selected topics from the ERBP Vascular Access Guideline
Markus Hollenbeck, Bottrop, Germany
Risk prediction models for elderly people with Chronic Kidney Disease: a risky business?
Maarten Taal, Derby, United Kingdom
Reading a systematic review: a hands-on experience
Christiane Drechsler, Würzburg, Germany
Why good guidance can save lives - or make them better
Evi Nagler, Ghent, Belgium
 
Rheumatology for nephrologists
My CKD patient has joint or back pain: a diagnostic primer for nephrologists
Julio Pascual, Barcelona, Spain
Sarcoidosis - How often do we miss renal involvement?
Speaker to be confirmed
Bacterial microbiota in ANCA Vasculitis: clinical implications on the good, bad, and ugly
Andreas Kronbichler, Innsbruck, Austria
Autoinfl ammatory diseases – an update for nephrologists
Birgit Kortus-Götze, Marburg, Germany
Antiphospholipid antibody syndrome: a catastrophic disease?
Ricard Cervera, Barcelona, Spain
Lupus: the ten top tips nephrologists must know
Frederic Houssiau, Brussels, Belgium
 
Oncology for nephrologists
Part I
Cytotoxic drugs and their effects on the kidney
Ben Sprangers, Leuven, Belgium
Kidney and cancer - a dangereux liason
Alicja Debska-Slizien, Gdansk, Poland
Targeted therapies in oncology and nephrotoxicity
Petra Tesarova, Prague, Czech Republic
Challenging but helpful Nephrology consults in the oncology ward
Jolanta Malyszko, Bialystok, Poland

Part II
Dialysis and malignancy - a growing problem
Maria Pippias, Amsterdam, The Netherlands
Patient with prior malignancy on the waiting list for transplantation
Bruno Watschinger, Vienna, Austria
From “primary” amyloidosis to monoclonal gammopathy of renal signifi cance - holistic approach to plasma cell dyscrasias
Elena Zakharova, Moscow, Russia
Oncology drugs in patients with CKD - a real challenge
Jan T. Kielstein, Braunschweig, Germany
 
Curso de Nefrologia
(Nephrology Course in Spanish)
logo
Mesa I: Introducción al Curso y Epidemiología de la Enfermedad Renal Crónica (ERC) en Iberoamérica
Introducción al Curso
Maria Dolores Del Pino Y Pino, Almería, España
Epidemiología de la ERC en Iberoamérica:
a) La realidad de Latinoamérica. ¿De qué
depende la heterogeneidad?
Walter Guillermo Douthat, Córdoba, Argentina
b) La realidad de España y Portugal: Desafíos a corto plazo
Speaker to be confirmed

Mesa II: Problemas en Nefrología:
Envejecimiento, salud renal y reflexiones sobre el futuro de la especialidad
Salud renal y economía: ¿Podemos aspirar a la sostenibilidad?
Angel Luis Martin de Francisco, Santander, España
Envejecimiento, senescencia celular y ERC. ¿Podríamos actuar?
Diego Rodriguez Puyol, Alcalá de Henares, España
Futuro de la Especialidad: ¿Qué dejar de hacer y en qué innovar?
Mariano Rodríguez-Portillo, Córdoba, España

Mesa III: Guías de Práctica Clínica y Cuestiones
Emergentes en Nefrología
CKD-MBD: ¿Correlacionan los marcadores bioquímicos con la histología ósea? La experiencia mundial K/DIGO
Ezequiel Bellorin-Font, Caracas, Venezuela
Enfermedad de Fabry: Estudio PREFINE, un desafío necesario
José-Vicente Torregrosa, Barcelona, España
¿Qué aportan las nuevas guías españolas de accesos vasculares?
José Ibeas, Barcelona, España
¿Es frecuente la hipertensión pulmonar en hemodiálisis? Factores implicados
Juan M. López-Gómez, Madrid, España
 
Practical issues in vascular access care
Vascular access stenosis: Steps in the diagnosis and management
Ramon Roca-Tey, Barcelona, Spain
Ultrasonography of the vascular access from theory to clinical practice
Simon Van Hooland, Ghent, Belgium
How to correct and avoid vascular access malposition
Maria Guedes Marques, Coimbra, Portugal
How to prevent and treat vascular access complications
José Ibeas, Barcelona, Spain
Central vein catheters in haemodialysis. How to improve its performance
Maurizio Gallieni, Milan, Italy
 
What adult nephrologists should know about childhood-onset kidney disorders
Diagnosis, management and outcomes of congenital and inherited kidney diseases along the age continuum
Elke Wuehl, Heidelberg, Germany
Early management and long-term outcomes of childhood idiopathic nephrotic syndrome
Nicholas Webb, Manchester, United Kingdom
Structured transition of pediatric patients to adult care: challenges and opportunities
Lars Pape, Hannover, Germany
Resist the beginnings: Preserving cardiovascular health in childhood-onset chronic kidney disease
Rukshana Shroff, London, United Kingdom
 
Variation in Pre-Dialysis nephrology care
The changing pattern of kidney diseases at dialysis onset
Vianda Stel, Amsterdam, The Netherlands
Are we able to really slow progression in CKD?
Dick De Zeeuw, Groningen, The Netherlands
The most prevalent one: Can we better handle diabetics and delay dialysis?
Peter Rossing, Gentofte, Denmark
How to avoid over- and underdiagnosis of Chronic Kidney Disease
Marc E. De Broe, Antwerp, Belgium
 
Geriatrics and rehabilitation of CKD patients – what should the nephrologist know?
Polypharmacy in elderly population with CKD - how to deal with it
Aud Høieggen, Oslo, Norway
CKD in the elderly - a growing epidemic or just a matter of normal eGFR decline
Peter Barany, Stockholm, Sweden
Anemia management in the elderly CKD patient
Francesco Locatelli, Lecco, Italy
Dialysis in the elderly and frail patients
Angel Luis Martin de Francisco, Santander, Spain
 
Education in nephrology
Joint Session Renal Section and Board of the UEMS & ERA-EDTA
logo

Introduction: The UEMS and ERA-EDTA Alliance
Jorge B. Cannata-Andía, Oviedo, Spain
The current status of European Nephrology Education
Talia Weinstein, Tel Aviv, Israel
Recruiting high calibre fellows into Nephrology:
Challenges and Solutions
Nadine Vogelsang, Münster, Germany
Progressing training harmonisation.
The “European Certifi cate in Nephrology”
David Lappin, Galway, Ireland
Knowledge-based examination in Nephrology:
The UK experience
Jonathan G. Fox, Glasgow, United Kingdom
Mapping future progress. Panel and audience general discussion lead by Anibal Ferreira, Lisbon, Portugal and Itzchak Slotki, Jerusalem, Israel

 
Emerging global causes of chronic kidney disease
Heat stress nephropathy
Richard J. Johnson, Denver, U.S.A.
Pathology of mesoamerican nephropathy
Annika Wernerson, Stockholm, Sweden
Proton pump inhibitors and kidney disease
Morgan Grams, Baltimore, U.S.A.
Narcotic drugs
Speaker to be confirmed
 
State of the art in Peritoneal Dialysis in 2017
Organised jointly with EuroPD
EuroPD
Starting a patient on PD: troubleshooting the first 3 months
Miguel Perez Fontan, La Coruña, Spain
Infectious problems in PD: from basic science to the bedside
Martin Wilkie, Sheffield, United Kingdom
Basic science in PD: translation for clinicians
(literature overview of major basic research in the last years)
Achim Joerres, Cologne, Germany
Transitions in ESRD: room for improvement?
Mark Lambie, Stoke-on-Trent, United Kingdom
 
Quality of life in people with kidney disease
What is quality of life, and how to measure it?
Friedo W. Dekker, Leiden, The Netherlands
Ways to improve quality of life in clinical practice
Fergus Caskey, Bristol, United Kingdom
The patient perspective on quality of life
Daniel Gallego-Azurro, Torrent (Valencia), Spain
Using quality of life in benchmark initiatives
Francesca Tentori, Ann Arbor, U.S.A.
 
Ethics
- Ethical aspects for programming animal studies
- Ethical aspects for programming clinical trials/observational studies
- Ethics of biobanking and use of biological samples
- Ethics for the use of stem cell or manipulated human cells
 
Special Session with European Medicines Agency
(EMA)
 
Special Interactive Session
Patient empowerment: an interactive “how to” experience
- Pitfalls in patient-physician communication
- Shared decision making in true life

In this highly interactive workshop session method acting, psycho-sociology and clinical patient encounters will be mix to enhance understanding and knowledge of some major problems when working with patients who take their care into their own hands.